Safety And Efficacy Of Adding Intravenous N-Acetyl Cysteine To Parenteral L-Alanyl L-Glutamine In Hospitalized Patients Undergoing Colon Surgeries

Not Applicable

• Conditions: Digestive System; Surgery; Anaesthesia

• Registration Number: PACTR201807118984852
• Lead Sponsor: ain shams universty

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-07-16
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 63

Inclusion Criteria

Patients aged between 18 and 80 years.
Need for ICU admission after colonic surgery.
Requirement of TPN for at least 5 days due to failure of or contraindication for enteral nutrition.
Signing a written informed consent

Exclusion Criteria

Patients with persistent hemodynamic instability (systolic blood pressure <80 mm Hg).
Renal impairment, hepatic insufficiency.
Severe or uncontrolled sepsis
Persistent metabolic acidosis.
Head trauma, heart failure,
Any sensitivity to components of L-alanyl L-glutamine (Dipeptiven®, Fresenius Kabi, Germany) or NAC

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
-evaluate the efficacy of NAC through assessing the changes in the serum level of malondialdehyde (MDA) as antioxidant marker ;evaluate changes in the tumor necrosis factor alpha (TNF-a) as anti-inflammatory marker

Secondary Outcome Measures

Name	Time	Method
safety evaluation by recording any side effect that may appear <br>